摘要
目的研究2型糖尿病肾病早期转化生长因子1β(TGF-1β)的变化及洛沙坦对其影响。方法选择2型糖尿病肾病早期患者62例,根据尿白蛋白排泄率(UAER)不同分为高UAER、低UAER两组,检测患者TGF-1β、血糖及肾功各指标,并与对照组比较;检测洛沙坦治疗前后患者上述指标的变化情况。结果糖尿病肾病患者UAER、TGF-1β均明显高于对照组(P<0.01),TGF-1β水平与UAER等肾功能指标呈正相关关系。洛沙坦治疗8周后,患者UAER及TGF-1β均明显下降,低UAER组下降更明显。结论糖尿病肾病患者TGF-1β水平与UAER呈正相关;洛沙坦能降低糖尿病肾病早期患者的TGF-1β水平并改善其肾功能。
[Objective] To study the： change of transforming growth factor-β1 （TGF-β1） in patients with diabetic nephropathy and it＇s intervention with valsartan. [Methods] 62 type 2 diabetes patients were divided into two groups according to the level of urinary albumin excretion rate （UAER）. The levels of TGF-β1, blood sugar and urinary renal function were measured in all patients and normal controls. Above markers were measured after valsartan was given. [Results] The levels of UAER and TGF-β1 in patients with diabetic nephropathy were significantly higher than that in normal controls （P〈0. 01）. The level of UAER positively correlated with the level of TGF-β1 in patients with diabetic nephropathy. After 8 weeks of valsartan therapy, the levels of UAER and TGF-β1 decreased significantly in patients with diabetic nephropathy. [Conclusion] There is a positive correlation between TGF-β1 and UAER in patients with diabetic nephropathy. ＇Valsartan can decrease the level of TGF-β1 and improve the renal function of oatients with diabetic nenhropathy.
出处
《山东医药》
CAS
北大核心
2007年第1期21-22,共2页
Shandong Medical Journal
基金
济南市卫生局科技发展计划项目(A0206)
关键词
2型糖尿病
糖尿病肾病
洛沙坦
转化生长因子Β
type 2 diabetes
diabetic nephropathies
valsartan
transforming growth factor beta
